OXIGENE (OXGN) Rips After Geting SPA From FDA for ZYBRESTAT Phase 3
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/20/2026
- Wall St set to open higher as chips recover, megacap earnings loom
- Oil steadies as hopes of renewed US-Iran negotiations offset Houthi threat
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
- Why Moonshot AI's Kimi K3 is actually bullish for memory stocks
- AMC Entertainment soars on record quarterly results
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Wall St set to open higher as chips recover, megacap earnings loom
- Oil steadies as hopes of renewed US-Iran negotiations offset Houthi threat
- IREN raises 2026 revenue target to $4bn after $2.8bn in contracts
- AMC Entertainment (AMC) Tops Q2 EPS by 16c
OXiGENE (OXGN) Announces Agreement With FDA on Special Protocol Assessment for a Phase 3 Trial of ZYBRESTAT(R) in Anaplastic Thyroid Cancer
September 17, 2012 4:07 PM EDTOXiGENE, Inc. (Nasdaq: OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that it has come to agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for its Phase 3 clinical trial (FACT 2) of ZYBRESTAT... More
